Vertex Pharmaceuticals Incorporated Company Profile (NASDAQ:VRTX)

Vertex Pharmaceuticals Incorporated trades on the NASDAQ under the ticker symbol "VRTX."

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) posted its quarterly earnings data on Thursday, April, 27th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.04 by $0.09. The firm earned $714.72 million during the quarter, compared to analyst estimates of $692.64 million. Vertex Pharmaceuticals Incorporated had a return on equity of 3.00% and a net margin of 8.64%. Vertex Pharmaceuticals Incorporated's revenue was up 79.5% on a year-over-year basis. During the same period in the prior year, the business posted $0.09 EPS. View Vertex Pharmaceuticals Incorporated's Earnings History.

Vertex Pharmaceuticals Incorporated is scheduled to release their next quarterly earnings announcement on Wednesday, July, 26th 2017. View Earnings Estimates for Vertex Pharmaceuticals Incorporated.

24 brokers have issued 1 year price objectives for Vertex Pharmaceuticals Incorporated's stock. Their predictions range from $81.00 to $200.00. On average, they anticipate Vertex Pharmaceuticals Incorporated's share price to reach $157.04 in the next year. View Analyst Ratings for Vertex Pharmaceuticals Incorporated.

Here are some recent quotes from research analysts about Vertex Pharmaceuticals Incorporated stock:

• 1. According to Zacks Investment Research, "Vertex has two CF drugs – Kalydeco & Orkambi – in its portfolio with blockbuster potential. Its efforts to get the drugs approved for additional indications are encouraging. Label expansion will increase the patient population and boost sales. Vertex’s CF pipeline is quite strong with a broad portfolio of next-generation CF correctors. Investor focus will now be on the triple combination CF regimens, which are crucial for long-term growth at Vertex. Multiple triple combo data readouts in CF patients are expected in 2H17. The stock has also done well this year. However, Vertex has faced many challenges with respect to commercialization of Orkambi in ex-U.S. markets due to re-imbursement hurdles and a slower-than-anticipated uptake in Germany. Estimates have also gone up slightly ahead of the company’s Q2 earnings release. The company has a positive record of earnings surprises in recent quarters." (7/4/2017)
• 2. Needham & Company LLC analysts commented, "Vertex announced 1Q17 financial results last night. Orkambi WW sales $295M beat our $277.5M and consensus $280M ests. Kalydeco WW sales $186M beat our $178.0M and consensus $175M ests. Mgmt raised Kalydeco, but left unch Orkambi guidance ($1.1-1.3B Orkambi and $710M-$730M from $690-710M Kalydeco). Orkambi driven by strong uptake and compliance in pediatric pts and Kalydeco driven by one time reimbursement in Europe. Our 2Q17 Orkambi and Kalydeco ests are $294.0M (was $287.5M) and $179.0M (was $178.0M). Stock reflects IVA/ TEZ commercial success and we maintain HOLD." (4/28/2017)
• 3. Maxim Group analysts commented, "Vertex reported 1Q17 with total CF revenue of $481M, which was above consensus of $444M, driven by both Orkambi and Kalydeco revenues beating estimates." (4/28/2017)
• 4. BMO Capital Markets analysts commented, "We believe Vertex's acquisition of Concert's CTP-656, a deuterated ivacaftor (Kalydeco), removes a key potential competitor in the cystic fibrosis space. In addition, CTP-656 could replace Kalydeco in the triple combo, allowing a once-daily (QD) regimen, which would offset an important advaVertex Pharma (NASDAQ: VRTX)ntage of Galapagos's QD triple combo in development. We also believe CTP-656's later patent expiration date (2032 vs. 2027 for Kalydeco) will be an important lifecycle management component of Vertex's cystic fibrosis franchise." (3/7/2017)
• 5. Robert W. Baird analysts commented, "Vertex announced plans to acquire Concert Pharmaceuticals' CTP-656, or deuterated ivacaftor. We think this acquisition highlights Vertex's commitment to defending its position as the leading CF company as it both eliminates a potential competitor and allows access to a once-daily modified version of ivacaftor with a longer patent life than ivacaftor itself. Overall, we think this is a smart deal for the company at a reasonable price, and reiterate our Outperform rating." (3/6/2017)

Some companies that are related to Vertex Pharmaceuticals Incorporated include Regeneron Pharmaceuticals (REGN), Exelixis (EXEL), TESARO (TSRO), Bioverativ (BIVV), Kite Pharma (KITE), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Clovis Oncology (CLVS), Intercept Pharmaceuticals (ICPT), Juno Therapeutics (JUNO), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals PLC (GWPH), BeiGene (BGNE), Agios Pharmaceuticals (AGIO), China Biologic Products (CBPO), AveXis (AVXS), Prothena Corporation PLC (PRTA) and Axovant Sciences (AXON).

Vertex Pharmaceuticals Incorporated's management team includes the folowing people:

• Jeffrey M. Leiden M.D. Ph.D., Chairman of the Board, President, Chief Executive Officer
• Ian F. Smith CPA, Chief Financial Officer, Chief Operating Officer, Executive Vice President
• Michael J. Parini J.D., Executive Vice President, Chief Legal and Administrative Officer
• David Altshuler M.D., Ph.D., Executive Vice President - Global Research, Chief Scientific Officer
• Stuart A. Arbuckle, Executive Vice President, Chief Commercial Officer
• Jeffrey A. Chodakewitz M.D., Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer
• Amit K. Sachdev J.D., Executive Vice President, Chief Regulatory Officer and Chief of Staff to the CEO
• Paul M. Silva, Senior Vice President, Corporate Controller
• Bruce I. Sachs, Lead Director, Independent Director
• Elaine S. Ullian, Co-Lead Independent Director

Vertex Pharmaceuticals Incorporated's stock is owned by many different of retail and institutional investors. Top institutional investors include Manning & Napier Advisors LLC (0.65%), Public Employees Retirement Association of Colorado (0.21%), Strs Ohio (0.14%), AMF Pensionsforsakring AB (0.13%), Atalanta Sosnoff Capital LLC (0.12%) and Chevy Chase Trust Holdings Inc. (0.10%). Company insiders that own Vertex Pharmaceuticals Incorporated stock include Amit Sachdev, David Altshuler, Elaine Ullian, Ian F Smith, Jeffrey Chodakewitz, Jeffrey M Leiden, Joshua S Boger, Michael Parini, Paul M Silva, Sangeeta N Bhatia, Stuart A Arbuckle and Yuchun Lee. View Institutional Ownership Trends for Vertex Pharmaceuticals Incorporated.

Vertex Pharmaceuticals Incorporated's stock was sold by a variety of institutional investors in the last quarter, including Manning & Napier Advisors LLC, APG Asset Management N.V., Factory Mutual Insurance Co., Gateway Investment Advisers LLC, Exxonmobil Investment Management Inc. TX, Capstone Asset Management Co., Hartford Investment Management Co. and Shell Asset Management Co.. Company insiders that have sold Vertex Pharmaceuticals Incorporated stock in the last year include Amit Sachdev, David Altshuler, Ian F Smith, Jeffrey Chodakewitz, Jeffrey M Leiden, Joshua S Boger, Michael Parini, Paul M Silva, Sangeeta N Bhatia and Stuart A Arbuckle. View Insider Buying and Selling for Vertex Pharmaceuticals Incorporated.

Vertex Pharmaceuticals Incorporated's stock was acquired by a variety of institutional investors in the last quarter, including Atalanta Sosnoff Capital LLC, Acadian Asset Management LLC, Russell Investments Group Ltd., Bank of Montreal Can, Mn Services Vermogensbeheer B.V., Cullinan Associates Inc., Oakbrook Investments LLC and National Pension Service. View Insider Buying and Selling for Vertex Pharmaceuticals Incorporated.

Shares of Vertex Pharmaceuticals Incorporated can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Vertex Pharmaceuticals Incorporated stock can currently be purchased for approximately $163.42.